Recent Quotes (30 days)

You have no recent quotes
chg | %

Hemostemix Inc  

(Public, CVE:HEM)   Watch this stock  
Find more results for CVE:TIK.P
0.000 (0.00%)
Aug 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 1.25
Open     -
Vol / Avg. 0.00/15,707.00
Mkt cap 46.06M
P/E     -
Div/yield     -
EPS -0.05
Shares 65.80M
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -101.75% -207.18%
Return on average equity -119.65% -243.48%
CDP Score - -


Suite 730

Website links


Hemostemix Inc. is a clinical-stage company developing and commercializing blood-derived cell therapies for medical conditions. The Company’s product (ACP-01) is an autologous (patient-derived), blood-derived cell therapy, which has been the subject of three clinical trials to-date, two for critical limb ischemia and one for angina pectoris. The Hemostemix technology relates to a population of cells (the SCP) derived from a simple blood draw, the process for isolating those cells, and then the enrichment and differentiation of those cells into various cell lineages. It has developed processes to separate the SCP and then control its differentiation into different cell types in culture.